Omeros Corporation (OMER) Investment Analysis
1. Executive Summary:
Omeros Corporation is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications, with a core emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders [cite: 1, 2]. The company's commercial operational foundation underwent a structural shift following the U.S. Food and Drug Administration (FDA) approval of Yartemlea (narsoplimab-wuug) in late December 2025 [cite: 3, 4, 5]. Yartemlea is the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an ultra-orphan, highly lethal complication of stem cell transplantation [cite: 3, 6].
Omeros generates its core revenue from net product sales of Yartemlea in the United States, supplemented by milestone-based payments and licensing fees from its development partners, notably Novo Nordisk [cite: 6, 7, 8]. The company's customer base is comprised of specialized biopharmaceutical wholesalers and distributors that supply major bone marrow transplant centers and hospital outpatient clinics across North America [cite: 8, 9, 10]. Geographically, while immediate revenues are concentrated in the United States, Omeros holds a global development footprint through international clinical registries and regulatory filings in the European Union [cite: 3, 11, 12].
| Key Revenue Stream |
Underlying Product/Asset |
Primary Customer Segment |
Geographic Focus |
| Net Product Sales |
Yartemlea (narsoplimab-wuug) [cite: 3, 6] |
Specialty Distributors, Wholesalers, Transplant Centers [cite: 8, 9] |
United States [cite: 8, 9] |
| Milestones & Royalties |
Zaltenibart (formerly OMS906) [cite: 1, 7] |
Novo Nordisk (Global Licensee) [cite: 1, 7] |
Global (U.S., Europe, Japan) [cite: 7, 13] |
| Legacy Monetizations |
Omidria (ophthalmology asset) [cite: 14, 15] |
DRI Healthcare Trust (Royalty Purchaser) [cite: 16, 17] |
United States (Milestones only) [cite: 16] |
Concise Explanations of Strategic Operational Core
- Core Products and Services: The primary commercial product is Yartemlea, a fully human monoclonal antibody designed to inhibit mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector enzyme of the lectin complement pathway [cite: 3, 18, 19]. By blocking MASP-2, Yartemlea prevents the endothelial cell injury, microvascular thrombosis, and localized cellular damage that drive TA-TMA pathogenesis [cite: 3, 19].
- Primary Customer Types: The primary purchasing entities are specialized pharmaceutical distributors and high-volume clinical institutions, primarily bone marrow transplant departments within academic medical centers and pediatric oncology hospitals [cite: 5, 8, 9]. Treatment decisions are directed by transplant physicians and clinical hematologists [cite: 9, 20].
- Most Important End Markets: The addressable market is concentrated in pediatric and adult patients undergoing allogeneic (donor cell) or autologous hematopoietic stem cell transplants who subsequently exhibit high-risk TA-TMA [cite: 3, 21]. Severely presenting cases represent an ultra-orphan population with historical one-year survival rates as low as 17% to 44% in untreated pediatric patients and 17% to 58% in adults [cite: 12, 22].
- Why Customers Choose Omeros: Clinicians select Yartemlea because it is the only regulatory-approved drug specifically indicated for TA-TMA [cite: 3, 5, 22]. Mechanistically, its selective inhibition of the lectin complement pathway preserves the classical and alternative pathways, which are essential for standard adaptive immune responses and defense against encapsulated bacterial infections [cite: 3, 18, 19]. This highly targeted therapeutic profile contrasts favorably with off-label alternatives that broadly suppress the immune system, such as terminal C5 complement inhibitors [cite: 3, 18, 22].
2. Business Drivers & Strategic Overview:
Product and Service Detail
Yartemlea is distributed as a single-dose vial priced at approximately $36,000 [cite: 5, 23, 24]. The clinical dosing protocol is weight-dependent [cite: 25]. Patients weighing 50 kilograms or more receive a recommended dose of 370 milligrams via a 30-minute intravenous infusion once weekly, which can be increased to twice weekly if clinical indicators do not show sufficient improvement [cite: 25]. Pediatric and adult patients weighing under 50 kilograms are dosed at 4 milligrams per kilogram once weekly, with a similar potential to escalate to a twice-weekly frequency [cite: 25].
Across the pivotal clinical trials and the expanded access program (EAP), the median utilization was 8 to 10 vials per treatment course [cite: 5, 21, 24]. This standard course translates to an absolute therapeutic cost of $288,000 to $360,000 per patient [cite: 24, 26]. Realized net pricing is estimated at approximately $250,000 per patient course after adjusting for wholesaler distribution fees, chargebacks, and clinical rebates [cite: 9, 26].
Moat Analysis
Omeros’ competitive moat is anchored in intellectual property, biological selectivity, regulatory designations, and high switching barriers [cite: 3, 18, 27].
┌────────────────────────────────────────────────────────┐
│ OMEROS COMPETITIVE MOAT │
├────────────────────────────────────────────────────────┤
│ 1. BIOLOGICS REGULATORY EXCLUSIVITY │
│ - 12-Year U.S. Biologics Price Competition/Patent │
│ Term Exclusivity under the BLA pathway │
├────────────────────────────────────────────────────────┤
│ 2. TARGET PATENTS (MASP-2 & MASP-3) │
│ - Composition-of-matter & method-of-use coverage │
│ - Direct block on biosimilar lectin pathway entry │
├────────────────────────────────────────────────────────┤
│ 3. INFRASTRUCTURE & SWITCHING COSTS │
│ - Early clinical integration in pediatric & adult │
│ bone marrow transplant registries │
│ - Broad formulary listing at top transplant centers │
└────────────────────────────────────────────────────────┘
Because Yartemlea was approved as a biologic via a Biologics License Application (BLA) in late December 2025, it is granted a statutory 12-year period of regulatory exclusivity in the United States, protecting the asset from biosimilar competition regardless of patent challenges [cite: 3, 4, 25, 28]. The company’s robust patent estate covers the composition-of-matter and method-of-use for human monoclonal antibodies targeting MASP-2, providing a legal barrier to entry that prevents competitors from targeting the lectin pathway’s biological trigger [cite: 3, 18, 27].
Switching costs are high because bone marrow transplant centers must incorporate Yartemlea into pre-specified institutional clinical protocols [cite: 8, 9]. Once a center adds Yartemlea to its Pharmacy and Therapeutics (P&T) formulary, clinicians establish standardized treatment pathways, creating institutional lock-in [cite: 5, 8, 9].
Total Addressable Market (TAM) Analysis
The total addressable market is derived from the clinical incidence of TA-TMA within the broader hematopoietic stem cell transplant population [cite: 3, 21]. Approximately 11,000 allogeneic (donor cell) transplants are performed in the United States each year [cite: 21]. Up to 56% of allogeneic transplant recipients develop some degree of post-transplant thrombotic microangiopathy [cite: 3]. While mild cases may resolve with immunosuppressant modification, approximately 20% to 30% present as high-risk, severe cases requiring targeted systemic intervention [cite: 3, 26, 29].
$\text{US Allogeneic Transplants} = 11,000 \text{ annually} \text{ [cite: 21]}$$\text{Max TA-TMA Clinical Incidence} = 56\% \text{ of allogeneic recipients} \text{ [cite: 3]}$$\text{Estimated Severe High-Risk Case Cohort} \approx 2,000 \text{ to } 3,000 \text{ patients in the U.S.} \text{ [cite: 26, 30]}$
Applying a conservative net realized cost of $250,000 per patient course to this cohort of 2,000 to 3,000 patients yields a total addressable market of $500 million to $750 million in the United States alone [cite: 26, 30]. The European market expands this potential, with approximately 19,000 allogeneic transplants performed annually [cite: 3, 21], bringing the combined U.S. and European clinical opportunity to over $1.5 billion annually at peak penetration [cite: 26, 30].
Competitive Landscape
The competitive dynamics in the TA-TMA space changed in late July 2026, when AstraZeneca’s Alexion unit announced that its terminal C5 complement inhibitor, Ultomiris (ravulizumab), failed to meet its primary endpoint in the Phase 3 ALXN1210-TMA-313 clinical trial [cite: 12, 22, 31]. This randomized, double-blind, placebo-controlled study enrolled 146 adult and adolescent patients but failed to show statistical significance for event-free survival over 26 weeks compared to placebo [cite: 12, 22].
| Competitor / Asset |
Target System / Pathway |
Indication Status |
Clinical/Regulatory Position |
| Omeros (Yartemlea) |
Lectin Pathway (MASP-2) [cite: 3, 18] |
Approved (Adult & Pediatric $\ge$ 2 years) [cite: 3, 5] |
Gaining market share [cite: 32]. Holds exclusive approved status in the U.S. [cite: 22]. |
| AstraZeneca (Ultomiris) |
Terminal C5 Pathway [cite: 12, 22] |
Failed Phase 3 Adult Trial [cite: 22, 31]; Pediatric Filings Pending [cite: 12, 22] |
Losing ground [cite: 22]. High-risk adult segment is closed; pediatric regulatory filings are ongoing [cite: 12, 22]. |
| Off-Label Options (Eculizumab) |
Terminal C5 Pathway [cite: 20] |
Off-label use in transplant TMA [cite: 20] |
Holding ground but faces structural reimbursement headwinds due to J-code and NTAP [cite: 20, 33, 34]. |
AstraZeneca continues to advance regulatory filings for Ultomiris in pediatric patients based on its successful open-label trial (ALXN1210-TMA-314) [cite: 12, 22]. However, the adult trial failure leaves Omeros’ Yartemlea as the only approved therapy for the high-risk adult post-transplant market [cite: 3, 5, 22]. This strengthens Omeros' commercial positioning and supports its market share gains as hospitals transition from off-label alternatives [cite: 32, 33].
3. Financial Performance & Valuation:
Latest Quarterly Results (Q2 2026)
Omeros Corporation reported its second-quarter financial results for the period ending June 30, 2026, on Wednesday, August 12, 2026, after the market closed [cite: 1, 6].
- Revenue Performance: The company reported net product sales of $28.529 million, driven by the commercial scaling of Yartemlea [cite: 33, 34]. This represented a significant sequential increase of 188% compared to net product sales of $9.893 million in the first quarter of 2026 [cite: 6, 9, 35]. In contrast, net product sales for the second quarter of 2025 were zero [cite: 33].
- Gross Profit and Cost of Goods Sold: Cost of product sales was $0.798 million, yielding an operational gross profit of $27.731 million and a gross margin of 97.2% [cite: 33].
- Operational Expenses: Research and development (R&D) expenses declined approximately 37% year-over-year to $13.8 million, down from $22.0 million in the prior-year period, as clinical trial costs for zaltenibart shifted to Novo Nordisk [cite: 33, 36]. Selling, general, and administrative (SG&A) expenses increased 34% year-over-year to $13.9 million, driven by commercial launch costs for Yartemlea [cite: 33, 36]. Combined R&D and SG&A expenses totaled $27.7 million, compared with $26.7 million in the first quarter of 2026 [cite: 6].
- Operating Profitability: Omeros achieved an operating profit of $0.074 million for the second quarter of 2026 [cite: 33]. This operating breakeven represents a significant improvement compared to an operating loss of $17.421 million in the first quarter of 2026 and an operating loss of $32.354 million in the second quarter of 2025 [cite: 9, 33].
- GAAP Net Income vs. Adjusted Earnings: GAAP net income was $13.232 million, or basic EPS of $0.18 and diluted EPS of $0.15 [cite: 33]. This result was boosted by a non-cash mark-to-market gain of $11.447 million on the embedded derivative liability associated with the outstanding 2029 unsecured convertible notes [cite: 6, 33, 34]. Excluding these fair-value derivative adjustments, Omeros reported non-GAAP adjusted net income of $1.785 million, or adjusted EPS of $0.02 [cite: 6, 33, 34].
- Comparison to Analyst Estimates: Consensus estimates compiled by analysts projected a Q2 2026 revenue of $12.67 million to $12.69 million and a consensus adjusted EPS loss of $(0.25) to $(0.27) [cite: 32, 37, 38]. Omeros’ actual net revenue of $28.529 million and adjusted EPS of $0.02 exceeded analyst expectations across both metrics [cite: 32, 33].
Guidance Updates & Management Commentary
Management did not issue quantitative net product sales guidance for the remainder of fiscal year 2026, citing early-stage market dynamics [cite: 8]. However, key qualitative and structural updates were provided:
- Cash Flow Run-Rate: Based on Yartemlea’s launch trajectory, the product line was cash-flow positive in its first full launch quarter [cite: 8]. Management reiterated its projection that the entire company will achieve positive operating cash flow within 18 months of launch, placing the target timeline by mid-2027 [cite: 8, 39].
- Debt Restructuring Impact: In July 2026, Omeros completed the repurchase of $30.5 million aggregate principal amount of its 2029 Notes for a cash outlay of $60.2 million [cite: 34, 35]. This transaction reduced the remaining outstanding principal on the 2029 Notes to $40.3 million [cite: 34, 35]. This liability reduction cut future contractual cash interest by $8.6 million and reduced the aggregate number of potential dilutive shares upon conversion from 11.4 million to 6.5 million [cite: 32, 34, 35].
- Reimbursement Catalysts: Management highlighted that the permanent J-code (J1289) became effective July 1, 2026, simplifying outpatient billing [cite: 19, 33, 34]. The granted NTAP status, effective October 1, 2026, will provide up to $287,079 in additional Medicare reimbursement per qualifying hospital inpatient, supporting broader clinical adoption [cite: 33, 34, 40].
Impact on Stock Price and Analyst Sentiment
Following the earnings release on August 12, 2026, Omeros’ stock experienced a positive reaction, climbing over 13% in after-hours trading, driven by the revenue beat and positive adjusted profitability [cite: 32]. Analyst sentiment remained favorable, with H.C. Wainwright maintaining its Buy rating and $33.00 price target on the stock [cite: 41], and broader Wall Street consensus pointing to a Moderate-to-Strong Buy rating with an average target price of approximately $32.43 to $38.00 [cite: 42, 43, 44].
Financial Drivers of Valuation
To connect Omeros' valuation to its underlying business model, investors should focus on the following key variables:
┌────────────────────────────────────────────────────────┐
│ CORE VALUATION DRIVERS (FY 2026-2031) │
├────────────────────────────────────────────────────────┤
│ * 5-Year Net Sales CAGR: Projected at 44.5% │
│ - Driven by U.S. TA-TMA market penetration │
│ - Potential European turnaround & label expansions │
├────────────────────────────────────────────────────────┤
│ * Gross Margin Stability: Maintained at ~97% │
│ - Minimal marginal product cost │
│ - Incremental sales flow directly to EBIT │
├────────────────────────────────────────────────────────┤
│ * Strategic Cash Backstop: $2.1B Novo Nordisk Deal │
│ - High-teens royalties & regulatory milestones │
│ - Funds long-term pipeline (OncotoX-AML) │
└────────────────────────────────────────────────────────┘
The underlying assets, including the long-acting MASP-2 antibody OMS1029 and the preclinical OncotoX-AML candidate OMS805, provide long-term growth potential [cite: 2, 6, 9].
4. Risk Assessment & Macroeconomic Considerations:
To evaluate Omeros' outlook, its corporate risks are categorized by their source, impact, and potential long-term damage to the business model [cite: 39].
Risk Typologies
- Company-Specific Execution Risks: Clinical adoption of Yartemlea relies on early diagnosis [cite: 8]. If transplant centers only utilize the drug as a late-stage salvage therapy after multiorgan failure has occurred, clinical response rates will drop below the 61% pivotal trial average [cite: 18, 19, 45]. This would limit utilization and cap peak product sales [cite: 39, 45].
- Competitive Risks: Despite AstraZeneca’s Phase 3 adult clinical trial failure [cite: 22], clinicians may continue off-label utilization of terminal C5 inhibitors (such as eculizumab) due to historical familiarity [cite: 20]. In addition, if AstraZeneca secures FDA approval for Ultomiris in the pediatric TA-TMA market, it would create a competitive alternative in the pediatric segment, which represents a key driver of early adoption for Omeros [cite: 8, 12, 22].
- Customer Concentration and Demand Risks: High-volume bone marrow transplants are concentrated in a small number of specialized academic medical centers [cite: 8, 26]. The top 80 U.S. transplant centers perform approximately 80% of all procedures [cite: 5]. Any failure to secure and maintain formulary access within these top 80 centers would significantly restrict the drug’s commercial reach [cite: 5, 39].
- Regulatory and Legal Risks: The EMA’s CHMP issued a negative opinion on Omeros' marketing authorization application for narsoplimab in June 2026, citing concerns regarding the lack of a randomized control group [cite: 20, 33, 34]. While Omeros has requested a re-examination, a final negative decision would permanently block commercial access to the European market [cite: 20, 33, 34].
- Balance Sheet and Capital Allocation Risks: Although the company holds $132.0 million in cash and short-term investments [cite: 33, 34], its Omidria royalty streams have been fully monetized to DRI Healthcare Trust through 2031 [cite: 16]. Omeros is eligible for milestone payments of up to $27.5 million each in January 2026 and January 2028 [cite: 16], but the lack of ongoing royalty cash receipts places the burden of funding pipeline R&D entirely on Yartemlea’s sales ramp and Novo Nordisk milestones [cite: 7, 8, 39].
- Macroeconomic Sensitivities: Inflationary pressures can impact biological manufacturing costs and supply chains [cite: 27]. Additionally, any changes in federal healthcare policy or private insurance reimbursement structures for orphan drugs could pressure gross-to-net adjustments, which currently stand at 11.5% [cite: 6, 35].
Structural Risk Framework
HIGH RISK / IMPACT
┌───────────────────────────────────────┐
│ │
│ * CHMP Reexamination Fails │
│ (ex-US locked out) │
│ │
│ * Clinicians Restrict Yartemlea │
│ to Late Salvage Therapy │
│ │
└──────────────────┬────────────────────┘
│
│
┌──────────────────┴────────────────────┐
│ │
│ * AstraZeneca Pediatric Approval │
│ & Off-Label Clinical Push │
│ │
│ * Delayed Development Milestones │
│ for Zaltenibart │
│ │
└───────────────────────────────────────┘
LOW RISK / IMPACT
- What Could Go Wrong: Yartemlea’s U.S. sales ramp plateaus as clinicians restrict its use to salvage therapy [cite: 39, 45], while the European Medicines Agency finalizes its rejection, permanently blocking ex-U.S. commercial revenues [cite: 20, 33, 34].
- Early Warning Signs: A sequential flattening or decline in Yartemlea's net product sales in subsequent quarters (Q3 or Q4 2026) [cite: 20], alongside a delay in the initiation of the investigator-sponsored trials or Phase 2 programs for OMS1029 by year-end 2026 [cite: 33, 34].
- Long-Term Thesis Damage: A termination of the Novo Nordisk agreement due to unexpected clinical safety issues in the Phase 3 zaltenibart program, combined with a stalled U.S. Yartemlea launch [cite: 7, 39, 46]. This would exhaust Omeros' cash reserves and force the company to raise highly dilutive capital or face renewed restructuring concerns [cite: 39, 47].
5. 5-Year Scenario Analysis:
This scenario analysis projects Omeros Corporation's financial trajectory and share price over a five-year horizon (through fiscal year 2031), using a current share price of $13.59 [cite: 48] and basic shares outstanding of 72.38 million as of August 2026 [cite: 42, 49].
High Case: Global Commercial Success (25% Probability)
- Key Fundamentals: Yartemlea achieves strong adoption in the United States and secures a regulatory turnaround in Europe via the re-examination process, leading to a commercial partnership and launch in the EU by late 2027 [cite: 20, 33, 34]. Year 5 U.S. net product sales scale to $350 million, and European net sales reach $150 million [cite: 26, 30]. Zaltenibart achieves clinical success under Novo Nordisk, triggering $50 million in annual high-margin milestone recognitions and early royalty streams [cite: 7, 8, 46].
- Operating Assumptions: Year 5 total revenue reaches $550 million, reflecting a 5-year sales CAGR of 59.8% from the current run-rate. Strong operating leverage on fixed manufacturing and corporate overhead drives a 40% net income margin, resulting in Year 5 net income of $220 million.
- Capital Structure & Dilution: Operating cash flow is used to retire the remaining 2029 convertible notes [cite: 34, 35]. Diluted share count increases slightly to 75.0 million due to employee stock option exercises [cite: 50, 51].
- Valuation Bridge: Applying an exit P/E multiple of 25.6x on Year 5 EPS of $2.93 yields an implied share price of $75.00 [cite: 52].
Base Case: Consistent U.S. Adoption (60% Probability)
- Key Fundamentals: Yartemlea establishes standard-of-care status in the United States, supported by J-code and NTAP billing structures [cite: 33, 34]. U.S. net sales scale to $220 million [cite: 26, 30]. The European application is denied, and ex-U.S. revenue is limited to minor compassionate-use programs [cite: 33, 34]. Zaltenibart progresses on track, generating $30 million in recognized development milestones in Year 5 [cite: 7, 8].
- Operating Assumptions: Year 5 total revenue reaches $250 million, reflecting a 5-year sales CAGR of 44.5%. Leverage on SG&A is moderate, and continuous pipeline investments in OMS1029 and OncotoX-AML limit net income margins to 30%, resulting in Year 5 net income of $75 million [cite: 6, 9, 53].
- Capital Structure & Dilution: The 2029 convertible notes are retired at maturity using accumulated cash [cite: 9, 35]. Diluted share count settles at 78.0 million.
- Valuation Bridge: Applying an exit P/E multiple of 36.4x on Year 5 EPS of $0.96 yields an implied share price of $35.00 [cite: 52].
Low Case: Restricted Adoption & Pipeline Delays (15% Probability)
- Key Fundamentals: Yartemlea’s clinical adoption is constrained by clinician preference for off-label salvage regimens, keeping U.S. sales at $70 million [cite: 45]. European approval is permanently denied [cite: 33, 34]. Zaltenibart experiences clinical development delays, and no milestones are recognized in Year 5 [cite: 7, 46].
- Operating Assumptions: Year 5 total revenue stalls at $80 million, representing a 15.6% CAGR. High fixed costs and R&D expenses lead to an operating loss, with a net income margin of -10% (loss of $8 million) [cite: 33, 39].
- Capital Structure & Dilution: To fund pipeline operations, Omeros utilizes its ATM facility, diluting the share count to 95.0 million [cite: 39, 54].
- Valuation Bridge: The equity is valued on a distressed Price-to-Sales (P/S) multiple of 5.9x on Year 5 revenue, yielding an implied share price of $5.00 [cite: 52].
Scenario Planning Summary
| Scenario |
Year 5 Revenue |
Margin / Earnings Assumption |
Valuation Multiple Assumption |
Current Share Price |
Implied Year 5 Share Price |
5-Year Total Return |
Annualized Return |
Probability |
| High Case |
$550M |
40% Net Margin / $220M Net Income |
25.6x P/E |
$13.59 [cite: 48] |
$75.00 [cite: 52] |
451.9% [cite: 52] |
40.7% [cite: 52] |
25% |
| Base Case |
$250M |
30% Net Margin / $75M Net Income |
36.4x P/E |
$13.59 [cite: 48] |
$35.00 [cite: 52] |
157.5% [cite: 52] |
20.8% [cite: 52] |
60% |
| Low Case |
$80M |
-10% Net Margin / $8M Net Loss |
5.9x P/S |
$13.59 [cite: 48] |
$5.00 [cite: 52] |
-63.2% [cite: 52] |
-18.1% [cite: 52] |
15% |
| Weighted |
$299.5M |
$104.3M Net Income equiv. |
17.2x Blend |
$13.59 [cite: 48] |
$40.50 |
198.0% |
24.4% |
100% |
ASYMMETRIC RISK PROFILE
6. Qualitative Scorecard:
This scorecard evaluates Omeros Corporation on ten qualitative metrics using a 1-10 scale. This evaluation is for educational and informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any transaction.
OMEROS QUALITATIVE PROFILE (1 - 10)
┌────────────────────────────────────────────────────────┐
│ Market Position: 9/10 │
├────────────────────────────────────────────────────────┤
│ Analyst Sentiment: 9/10 │
├────────────────────────────────────────────────────────┤
│ Capital Allocation: 8/10 │
├────────────────────────────────────────────────────────┤
│ Growth Outlook: 8/10 │
├────────────────────────────────────────────────────────┤
│ Revenue Quality: 8/10 │
├────────────────────────────────────────────────────────┤
│ Financial Health: 7/10 │
├────────────────────────────────────────────────────────┤
│ Business Viability: 7/10 │
├────────────────────────────────────────────────────────┤
│ Management Alignment: 6/10 │
├────────────────────────────────────────────────────────┤
│ Profitability: 6/10 │
├────────────────────────────────────────────────────────┤
│ Track Record: 4/10 │
└────────────────────────────────────────────────────────┘
Qualitative Evaluation Metrics
- Management Alignment: 6/10
Co-Founder and CEO Gregory A. Demopulos holds a direct 2.03% stake in the common equity [cite: 55, 56]. While his 32-year tenure provides leadership stability, executive compensation has historically been high, with total compensation reaching $17.8 million in 2025 [cite: 55, 57]. Dilution risks are present through ongoing option grants, such as a 1,000,000-option award granted to the CEO in July 2026 [cite: 50]. Other corporate insiders have engaged in regular open-market stock sales [cite: 49, 58].
- Revenue Quality: 8/10
Yartemlea’s high gross margins (97.2%) support strong cash generation as sales volume expands [cite: 33, 34]. However, because Omeros has fully monetized its Omidria royalties to DRI Healthcare Trust through 2031, near-term revenue diversity is limited [cite: 16]. Omeros remains dependent on Yartemlea's sales ramp and partner milestone payments to support operations [cite: 7, 8, 39].
- Market Position: 9/10
Omeros holds exclusive FDA-approved status in the U.S. post-transplant TA-TMA market, which was strengthened by the Phase 3 adult trial failure of AstraZeneca’s Ultomiris [cite: 3, 22, 43].
- Growth Outlook: 8/10
The near-term growth outlook is supported by Yartemlea’s permanent J-code and the impending implementation of NTAP reimbursement in October 2026 [cite: 33, 34]. These systems reduce financial friction and support broader institutional adoption [cite: 40, 43]. Long-term optionality is provided by pipeline assets, including MASP-2 extensions (OMS1029) and OncotoX-AML [cite: 2, 6, 9].
- Financial Health: 7/10
With $132.0 million in cash and short-term investments as of June 30, 2026, and positive operating cash flow of $4.1 million in Q2 2026, the company's balance sheet has stabilized [cite: 33, 34]. Outstanding debt on the 2029 Notes was reduced by 43% in July 2026, leaving $40.3 million in principal outstanding [cite: 35].
- Business Viability: 7/10
Target selectivity (MASP-2) is clinically robust and avoids the systemic infection risks associated with broad complement blockade [cite: 3, 18, 19]. Long-term viability depends on shifting clinical behavior from salvage therapy to early-line intervention and expanding Yartemlea into broader endothelial injury indications [cite: 6, 34, 45].
- Capital Allocation: 8/10
Management has prudently utilized cash from the Novo Nordisk transaction to retire senior secured debt [cite: 7, 10] and opportunistically buy back convertible notes and common stock [cite: 34, 35], reducing future interest obligations and dilution [cite: 34, 35].
- Analyst Sentiment: 9/10
Wall Street analysts remain highly constructive on Omeros [cite: 42, 43]. Out of seven active analysts covering the stock, consensus remains a Moderate-to-Strong Buy with median target price expectations between $32.43 and $38.00 [cite: 42, 43, 44].
- Profitability: 6/10
Omeros achieved positive non-GAAP adjusted earnings of $0.02 per share and operating breakeven in Q2 2026 [cite: 6, 33]. However, the company must sustain this trend over multiple quarters to establish consistent annual profitability [cite: 39].
- Track Record: 4/10
Historically, the company has experienced significant execution delays, clinical trial pauses to preserve capital, going-concern warnings, and share dilution [cite: 47, 54, 55]. The successful closing of the Novo Nordisk transaction and the commercial launch of Yartemlea represent execution successes that improve its operational track record [cite: 5, 7].
Qualitative Blended Score
- Blended Qualitative Score: 7.2 / 10
VALIDATED COMMERCIAL TRANSITION
7. Conclusion & Investment Thesis:
Omeros Corporation has transitioned from a high-risk development platform with balance sheet constraints to a commercial-stage orphan disease specialist [cite: 34, 39, 47]. This operational pivot is supported by Yartemlea’s status as the only FDA-approved therapy for adult TA-TMA, a position consolidated by AstraZeneca’s Phase 3 adult clinical trial failure [cite: 3, 22, 43].
The commercial launch of Yartemlea is supported by a permanent J-code and the implementation of inpatient NTAP reimbursement, which reduces financial friction for hospital adoption [cite: 33, 34, 40]. In addition, the upfront proceeds and ongoing milestone potential from the $2.1 billion Novo Nordisk deal provide non-dilutive capital to fund pipeline operations, reducing dilution risks for shareholders [cite: 7, 8, 39].
While the negative opinion from the EMA's CHMP in Europe represents a near-term headwind [cite: 33, 34], Omeros' current enterprise value of approximately $1.08 billion does not fully reflect the cash-generative potential of Yartemlea’s high-margin sales ramp combined with its pipeline assets [cite: 33, 39, 49].
This analysis is for educational and informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any transaction.
UNDERVALUED DISRUPTIVE BIOTECH
8. Technical Analysis, Price Action & Short-Term Outlook:
Omeros' stock exhibits strong technical momentum in mid-2026, trading at $13.59 [cite: 48] and holding above its 200-day simple moving average (SMA) of $11.12 [cite: 49]. The stock's short-term indicators, including a supportive 50-day SMA of $10.51 [cite: 49], suggest a robust bullish trend that was accelerated by the dual catalysts of AstraZeneca’s clinical miss and Yartemlea's NTAP status [cite: 43, 59]. Near-term resistance is identified at $14.29, with support established at $10.36 [cite: 60]. The short-term outlook is constructive, with expectations for consolidation as the market monitors Yartemlea's sales traction [cite: 20].
BULLISH TECHNICAL TREND
- Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026, https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-to-Announce-Second-Quarter-Financial-Results-on-August-12-2026/default.aspx
- Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment, https://investor.omeros.com/news/news-details/2026/Omeros-Announces-Upcoming-Presentation-at-EBMT-2026-Highlighting-Advances-in-TA-TMA-Treatment-03-21-2026/default.aspx
- Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA, https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Announces-Update-on-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx
- FDA Signals Flexibility with Recent Single-Arm Approvals - FDA Law Blog, https://www.thefdalawblog.com/2026/01/fda-signals-flexibility-with-recent-single-arm-approvals/
- Omeros (OMER) Q4 2025 Earnings Transcript - The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/06/01/omeros-omer-q4-2025-earnings-transcript/
- Omeros Corporation Reports Second Quarter 2026 Financial Results - Business Wire, https://www.businesswire.com/news/home/20260812018593/en/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results
- Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906), https://investor.omeros.com/news/news-details/2025/Omeros-Corporation-Announces-Closing-of-Asset-Purchase-and-License-Agreement-with-Novo-Nordisk-for-Omeros-Clinical-Stage-MASP-3-Inhibitor-Zaltenibart-OMS906-12-01-2025/default.aspx
- Omeros (OMER) Q1 2026 Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/05/14/omeros-omer-q1-2026-earnings-transcript/
- Omeros Corporation Reports First Quarter 2026 Financial Results, https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-First-Quarter-2026-Financial-Results/default.aspx
- ex_889301.htm - SEC.gov, https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/ex_889301.htm
- Form 10-Q for Omeros Corp filed 11/13/2025, https://s21.q4cdn.com/975996899/files/doc_financials/2025/q3/0001437749-25-034826.pdf
- Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant - AstraZeneca, https://www.astrazeneca.com/media-centre/press-releases/2026/update-on-ultomiris-phase-iii-trial-in-hsct-tma.html
- OMS-906 Sales Forecast, and Market Size Analysis – 2034 - DelveInsight, https://www.delveinsight.com/report-store/oms-906-sale-forecast-and-market-analysis
- Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical, https://investor.omeros.com/news/news-details/2023/Omeros-Corporation-Receives-200-Million-Milestone-Payment-from-Rayner-Surgical-02-06-2023/default.aspx
- Freshfields advises Rayner Surgical on its acquisition of OMIDRIA from Omeros in a transaction valued in excess of $1 billion, https://www.freshfields.com/en/our-thinking/news/news-search/2021/12/freshfields-advises-rayner-surgical-on-its-acquisition-of-omidria-from-omeros-in-a-transaction-valued-in-excess-of-$1-billion
- DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria®, Updates Deployment and CAGR Guidance, https://drihealthcare.com/dri-healthcare-trust-announces-the-expansion-of-its-royalty-entitlement-on-the-us-net-sales-of-omidria-updates-deployment-and-cagr-guidance/
- Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust | FirstWord Pharma, https://firstwordpharma.com/story/5659433
- Omeros Pipeline – Narsoplimab (MASP-2 Inhibitor), PPARγ Agonists, & More, https://www.omeros.com/pipeline/
- MASP-2 Inhibitor for TA-TMA | FDA Approved | YARTEMLEA® HCP, https://yartemlea.com/
- Omeros drops amid EU hurdle for transplant drug (OMER:NASDAQ) | Seeking Alpha, https://seekingalpha.com/news/4607732-omeros-drops-amid-eu-hurdle-transplant-drug
- Omeros prices transplant complication drug at $36,000 per dose - Trending Now Biotech, https://www.biotech-now.co.uk/article/324531/omeros-prices-transplant-complication-drug-at-36000-per-dose
- Ultomiris fails to beat placebo in adult HSCT-TMA trial, narrowing approval path to children, https://allsci.com/news/clinical-trials/ultomiris-misses-phase-iii-endpoint-in-adult-hsct-tma-leaving-pediatric-approval-path-intact/
- FDA Approves Yartemlea for Rare, Life-Threatening Stem Cell Transplant Complication, https://xtalks.com/fda-approves-yartemlea-for-rare-life-threatening-stem-cell-transplant-complication-4579/
- Why Did Omeros Stock Jump 5% In After-Hours Trading Today? - Stocktwits, https://stocktwits.com/news-articles/markets/equity/why-did-omeros-stock-jump-5-in-after-hours-trading-today/cmUGpkKR42x
- Label: YARTEMLEA- narsoplimab injection - DailyMed, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8ff990a-0d2e-433f-9615-b9b097448991
- OMER: A Biotech on the Rise : r/wallstreetbets - Reddit, https://www.reddit.com/r/wallstreetbets/comments/1tgr49w/omer_a_biotech_on_the_rise/
- Form 10-K for Omeros Corp filed 03/31/2026, https://s21.q4cdn.com/975996899/files/doc_financials/2025/q4/0001437749-26-010636.pdf
- Narsoplimab - Drug Targets, Indications, Patents - Patsnap Synapse, https://synapse.patsnap.com/drug/4a1a307d48fa4ae1a35f6c112fe323c4
- OMEROS CORP (Form: 10-K, Received: 03/31/2025 16:29:14) - EDGAR Online, https://content.edgar-online.com/ExternalLink/EDGAR/0001437749-25-010216.html?hash=db9922fb35bf1dccd247b37fd517fdf50dd19ccd7260cdff06f1fba705877d46&dest=ex_769657_htm
- OMER: A Biotech on the Rise : r/stocks - Reddit, https://www.reddit.com/r/stocks/comments/1svga6o/omer_a_biotech_on_the_rise/
- AstraZeneca's rare disease drug misses main goal in late-stage trial - PM360, https://pm360online.com/news/astrazenecas-rare-disease-drug-misses-main-goal-in-late-stage-trial/
- Omeros surges 13% on strong earnings and revenue beat - Investing.com NG, https://ng.investing.com/news/stock-market-news/omeros-surges-13-on-strong-earnings-and-revenue-beat-93CH-2656458
- Omeros Q2 2026 Earnings: YARTEMLEA Drives Operating Break-Even - TradingKey, https://www.tradingkey.com/news/earnings/262100429-tradingkey
- Omeros Corporation (NASDAQ: OMER) turns profitable as YARTEMLEA revenue surges and debt falls - Stock Titan, https://www.stocktitan.net/sec-filings/OMER/8-k-omeros-corp-reports-material-event-8a4a213b78f0.html
- Omeros Corporation Reports Second Quarter 2026 Financial Results - Stock Titan, https://www.stocktitan.net/news/OMER/omeros-corporation-reports-second-quarter-2026-financial-234ooq94o9gq.html
- Omeros Corp (OMER) Income Statement - Tradingkey.com, https://www.tradingkey.com/markets/stocks/omer/income-statement
- Earnings Preview: Omeros to Report Financial Results Post-market on August 12 - 富途资讯, https://news.futunn.com/en/post/77430178/earnings-preview-omeros-to-report-financial-results-post-market-on
- OMER Q2'26 Earnings: revenue estimate is 12.69M USD - TradingView, https://www.tradingview.com/news/tradingview:4ee2cbfca136d:0-omer-q2-26-earnings-revenue-estimate-is-12-69m-usd/
- Omeros (OMER) Has a Real Commercial Launch, but Europe and Cash Burn Still Matter, https://news.alphastreet.com/omeros-omer-has-a-real-commercial-launch-but-europe-and-cash-burn-still-matter/
- CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®, https://www.barchart.com/story/news/3611605/cms-grants-new-technology-add-on-payment-ntap-status-to-yartemlea
- H.C. Wainwright Maintains Omeros(OMER.US) With Buy Rating, Maintains Target Price $33, https://www.moomoo.com/news/post/73983822/hc-wainwright-maintains-omeros-omerus-with-buy-rating-maintains-target
- Omeros Stock Price | OMER Stock Quote, News, and History | Markets Insider, https://markets.businessinsider.com/stocks/omer-stock
- OMER Price: Quote, Forecast, Charts & News - Perplexity, https://www.perplexity.ai/finance/OMER?comparing=OMER,CORT,ALKS,SUPN,BMRN,DNLI
- Omeros (OMER) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/omer/forecast-price-target
- Omeros (Nasdaq:OMER) - Stock Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros
- Novo to Acquire Omeros's Experimental Therapy for Rare Blood and Kidney Diseases, https://globalgenes.org/raredaily/novo-to-acquire-omeross-experimental-therapy-for-rare-blood-and-kidney-diseases/
- Omeros (OMER) Balance Sheet & Financial Health Metrics - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/health
- Omeros Stock Price History - Investing.com, https://www.investing.com/equities/omeros-corp-historical-data
- Omeros Corporation (OMER) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/OMER
- Omeros Corp (OMER) awards CEO 1000000 stock options with 2036 expiry, https://www.stocktitan.net/sec-filings/OMER/form-4-omeros-corp-insider-trading-activity-918c19339a84.html
- omer20260331_10q.htm - SEC.gov, https://www.sec.gov/Archives/edgar/data/1285819/000143774926016720/omer20260331_10q.htm
- Untitled, unknown_url
- Omeros Corporation Reports First Quarter 2026 Financial Results, https://s21.q4cdn.com/975996899/files/doc_news/Omeros-Corporation-Reports-First-Quarter-2026-Financial-Results-2026.pdf
- Omeros Corporation Reports Second Quarter 2025 Financial Results, https://investor.omeros.com/news/news-details/2025/Omeros-Corporation-Reports-Second-Quarter-2025-Financial-Results-08-14-2025/default.aspx
- Omeros Corporation (OMER) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/management
- Omeros Corp Ownership Pattern for Jul-2026 - Insider, Institutional, Mutual Fund shareholdings - Trendlyne.com, https://us.trendlyne.com/us/equity/ownership/1554390/OMER/jul-2026/omeros-corporation/
- OMEROS CORP ($OMER) CEO 2025 Pay Revealed - Quiver Quantitative, https://www.quiverquant.com/news/OMEROS+CORP+%28%24OMER%29+CEO+2025+Pay+Revealed
- OMEROS CORP (OMER) - Insider Trading Form 4 Filings - SecForm4.Com, https://www.secform4.com/insider-trading/1285819.htm
- OMER - Omeros Corp Stock Price and Quote - Finviz, https://finviz.com/stock?t=OMER
- Omeros Corp (OMER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey, https://www.tradingkey.com/markets/stocks/omer/technical